Kidney

URCC-21038 ***Sites must enroll a Black patient and then be able to enroll a White patient within the following three months**

Disparities in REsults of Immune Checkpoint Inhibitor Treatment (DiRECT): A Prospective Cohort Study of Cancer Survivors Treated with anti-PD-1/anti-PD-L1 Immunotherapy in a Community Oncology Setting

---

S1931

Phase III Trial of Immunotherapy-Based Combination Therapy with or Without Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma (PROBE Trial)

---

URCC 18007

Randomized Placebo Controlled Trial of Bupropion For Cancer Related Fatigue

---

A031702 (Cohort B (adenocarcinoma of the bladder), E (penile cancer), F (sarcomatoid renal cell carcinoma), G (miscellaneous GU tract histologic variants), I (renal medullary carcinoma) and Cohort K (Renal Collecting Duct Carcinoma) are Temporarily Closed to Accrual)

Phase II Study of Cabozantinib in Combination with Nivolumab and Ipilimumab in Rare Genitourinary Tumors

---